BTL Industries Receives FDA Clearance to Expand EMFACE Platform for TMJ Dysfunction Treatment
Key Insights
BTL Industries (search) has received FDA clearance to expand its EMFACE (search) platform indications to include treatment of temporomandibular joint dysfunction (search) and associated pain relief.
The EMFACE (search) system combines synchronized radiofrequency and HIFES (search) technology to deliver non-invasive facial muscle stimulation without requiring surgery, injections, or medication.
The expanded indication allows dental and oral health providers to address TMJ dysfunction (search) while offering patients improved mandibular range of motion and muscle re-education benefits.
BTL Industries (search) announced that the FDA has cleared an expanded indication for its EMFACE (search) platform to treat temporomandibular joint (TMJ) dysfunction, marking a significant expansion of the device's therapeutic applications beyond its original facial muscle stimulation uses.
The EMFACE (search) system is now FDA-cleared for relief of symptoms associated with muscle spasm (search), treatment of TMJ dysfunction (search) and associated pain, muscle re-education, increased local blood flow, and maintenance or improvement of mandibular range of motion. This regulatory milestone positions the technology as a non-invasive treatment option for a condition that significantly impacts patient quality of life.
Technology Platform and Mechanism
EMFACE (search) combines synchronized radiofrequency and HIFES (search) (High-Intensity Focused Electromagnetic Stimulation) technology for facial muscle stimulation. The platform was developed through years of research and engineering to deliver therapeutic benefits without requiring surgery, injections, or medication, offering patients a non-invasive treatment alternative.
"EMFACE (search) is an established technology platform with multiple FDA-cleared uses," said David Chmel, CEO of BTL Industries (search). "This new indication allows dental, oral health, and wellness providers to address TMJ dysfunction (search) within its approved uses, expanding the benefits of EMFACE to more patients."
Clinical Impact and Provider Perspective
The expanded indication addresses a significant clinical need, as TMJ dysfunction (search) affects multiple aspects of patient wellbeing beyond jaw function. Dr. Shireen Dhanani, DMD, from Leesburg, Florida, emphasized the broader implications of the condition and treatment approach.
"TMJ dysfunction (search) impacts more than the jaw — it affects quality of life," said Dhanani. "With EMFACE (search), we can now offer an accessible, non-invasive option that not only helps patients find relief and functional improvement, but also expands the scope of dental care."
Company Background and Innovation Pipeline
Founded in 1993, BTL Industries (search) operates as a global leader in medical devices across more than 90 countries. The company maintains a robust research and development infrastructure with over 500 R&D engineers and holds more than 200 patents. BTL's product portfolio spans multiple therapeutic areas including dermatology, plastic surgery, orthopedics, joint and spine care, rehabilitation, dentistry, primary care, and OB/GYN applications.
The company's technology platform includes EMSCULPT NEO (search), EMFACE (search), EXION (search), EXOMIND (search), and EMSELLA (search), demonstrating its commitment to advancing medical treatments through technology and science across diverse clinical applications.
This FDA clearance represents BTL's continued expansion into new therapeutic areas, bringing science-backed technologies into additional areas of medicine to improve patient care and advance treatment options for healthcare providers worldwide.